Diffusion and DCE-MRI were performed at baseline and 2-3 days following Crolibulin (EPC2407) treatment in a phase 1 clinical study of this vascular disrupting agent (VDA). Several functional parameter maps were computed and co-registered across scan dates in 11 subjects with advanced solid tumors. We measured changes in these MRI parameters that indicate cell swelling and vascular reduction following treatment. We identified multivariate combinations of changes in these MRI parameters that are correlated with the dose, AUC and Cmax of Crolibulin, respectively, information that can guide Crolibulin dosing in clinical trials of this VDA in combination with cytotoxic drugs.
This abstract and the presentation materials are available to members only; a login is required.